THE #1 PRESCRIBED PARENTERAL THERAPY FOR PAH: REMODULIN® (treprostinil)1

  • More than 18 years’ experience2
  • No supply interruptions since launch in 2002
  • Remodulin has been recommended in guidelines for treatment of PAH since 20033
  • Flexible administration options of both SC and IV
  • Patient support programs, including financial support
  • Continuing innovation through development of new parenteral pumps
  • 27 clinical studies of SC/IV treprostinil in 4193 participating patients1

EXPERIENCE. CONSISTENCY. SUPPORT.

For more than 18 years, Remodulin patients and the healthcare professionals who care for them have been supported by United Therapeutics, a company dedicated to helping patients live with PAH. This trust and commitment are a part of why Remodulin is the #1 prescribed branded parenteral therapy for PAH.1,2

Remodulin has bioequivalent SC and IV administration options

Continuous subcutaneous infusion is the preferred administration method for Remodulin. Use IV infusion if subcutaneous infusion is not tolerated.2

SC Remodulin:

Patients can start SC Remodulin at home

No infusion-related bloodstream infections* reported in SC Remodulin clinical trials2

No mixing or reconstitution required2

Up to 3 days between refills4

*To reduce the risk of infection, aseptic technique must be used in the preparation and administration of Remodulin.

See a patient case study on transitioning from IV treatment to SC Remodulin.

Learn More

IV Remodulin:

Patients usually start treatment in the hospital4

No infusion site pain or infusion site reactions as commonly reported with SC administration5

Up to 2 days between pump refills6

Options available for mixing, including at-home premixing and the SPmix Program

Learn how to preserve your brand choice.

Why Remodulin?

Appropriate patients on IV Remodulin can participate in the SPmix Program, saving them time by not having to mix on their own.

Remodulin SPmix Enrollment Form

SC and IV Remodulin: Bioavailable within minutes, bioequivalent in less than 6 hours2,7

Remodulin has bioequivalent SC and IV administration options

Remodulin pharmacokinetics were analyzed in 51 healthy volunteers receiving IV or SC Remodulin at a dose of 10 ng/kg/min for 72 hours. Following a 4-day washout, volunteers were given the opposite route of their initial administration. Pharmacokinetics were then compared between IV and SC administration.7

Figure adapted from Laliberte K, et al. Cardiovasc Pharmacol. 2004, with permission.

Remodulin has a 4-hour half-life and can be delivered via SC or IV routes over 24 hours for patients who need continuous prostacyclin therapy.2

Identifying appropriate Remodulin patients

NYHA FC II-IV patients: Remodulin is indicated for FC II-IV patients2

High-risk and progressing patients: Remodulin is appropriate for high-risk and progressing patients who need quick intervention4,8

Learn more about managing risk

Patients transitioning from Flolan® (epoprostenol sodium): Flolan patients may benefit from transitioning to Remodulin because of the longer 4-hour half-life, reducing the risk of rebound pulmonary hypertension following hemodynamic compromise2,4

Learn more about transitioning patients from Flolan

The power of Remodulin

With an established clinical profile, Remodulin has been demonstrated to diminish symptoms associated with exercise and, for patients requiring transition from Flolan, slow the rate of clinical deterioration.2

27
clinical studies1
4193
participating patients1

Remodulin was launched in 2002 and has been recommended in guidelines for treatment of PAH since 2003.2,3

Remodulin has been included in the ACCF/AHA Consensus, 5th World Symposium, CHEST Treatment Recommendations, and ESC/ERS Treatment Guidelines.8-11

Learn more about treatment guidelines for patients in FC III and FC IV

Median change of +10 meters in 6MWD at week 122,12

In two 12-week, multicenter, randomized, double-blind, placebo-controlled trials, SC Remodulin infusion was compared to placebo in a total of 470 patients. The primary endpoint of these trials was the median change in 6MWD at week 12.2,12

  • Median change in the Remodulin group: +10 meters
  • Median change in the placebo group: 0 meters
  • Mean Remodulin dose: 9.3 ng/kg/min at 12 weeks
  • The most common adverse reactions: infusion site pain and reaction, headache, diarrhea, rash, nausea, jaw pain, vasodilatation, dizziness, edema, and hypotension
66
ng/kg/min

Average dose in real-world use of Remodulin1

Based on Specialty Pharmacy shipment data during January 2020. Dose data reported in Specialty Pharmacy shipments only. Limited to unique quarterly patients with dosing data.

6MWD=6-minute walk distance; ACCF=American College of Cardiology Foundation; AHA=American Heart Association; ERS=European Respiratory Society; ESC=European Society of Cardiology; FC=functional class; IV=intravenous; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension; SC=subcutaneous.

Informative video to share with your patients

Carey’s Story

Carey shares how she persevered and didn’t let her disease define her.

How to introduce patients to Remodulin

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

References: 1. Data on file. United Therapeutics Corporation. Research Triangle Park, NC. 2. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018. 3. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. 4. Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev. 2016;25(142):418-430. 5. Kingman M, Archer-Chicko C, Bartlett M, et al. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017;7(3):598-608. 6. Benza RL, Tapson VF, Gomberg-Maitland M, et al. One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant. 2013;32(9):889-896. 7. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin®) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44(2):209-214. 8. Galiè N, Humbert M, Vachiery JL, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37(1):67-119. 9. McLaughlin VV, Archer SL, Badesch DB, et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-2294. 10. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60-D72. 11. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449-475. 12. Simonneau G, Barst RJ, Galiè N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804.